New antibiotic candidate enters first human safety trial
NCT ID NCT07500181
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new experimental antibiotic, BAL2420, in 136 healthy adults. The goal is to check if it is safe and how the body processes it. Researchers will give single or multiple doses and watch for side effects. This is a first step toward possibly using it to treat severe bacterial infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BAL2420 (an experimental antibiotic)
- What this could lead to
- If successful, this could lead to a new treatment option for serious infections caused by Gram-negative bacteria.
- What could go wrong
- This is a very early Phase 1 safety study in healthy people, not patients. The drug may not work or may have side effects. Many early-stage drugs never reach the market.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ICON Early Clinical & Bioanalytical Solutions
RECRUITINGGroningen, 9728 NZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test